Antibacterial textiles are shifting from a 'concept add-on' to a 'basic functional requirement', yet the lagging evaluation system lacks a credible benchmark for this transformation. Recently, a critical national standard revision passed review in Zhejiang, sending a clear signal of industry upgrade.
Background
The standard under review is 'Textiles – Evaluation of Antibacterial Performance – Part 2: Absorption Method', part of the GB/T 20944 series implemented since 2007. The series includes three parts: agar diffusion, absorption, and shaking flask methods. The revision for the shaking flask method was assigned in June 2024 and is now in approval; the absorption method revision was assigned in June 2025, and this review marks its final stage.
The revision is driven by real industrial changes. Antibacterial technology has expanded from underwear and socks to sportswear, medical textiles, and home soft furnishings, with new materials and processes emerging. The original standards' test methods and scope can no longer match current needs. The participation of testing bodies, research institutes, brand companies, and new material firms reflects a cross-chain consensus.
Industrial Impact
The revision affects buyers and factories in three ways. First, test reliability will improve. The absorption method simulates liquid conditions such as sweat; the new standard will align more closely with actual wear scenarios, reducing disputes over 'effective in lab, ineffective in practice'. Second, marketing claims will be tightened. Many brands have used 'antibacterial' as a selling point without unified evaluation; after the new standard, claims must be backed by specified test methods, shrinking room for concept hype. Third, export technical barriers will lower. Antibacterial performance is a key concern in European and American markets; aligning domestic standards with international methods helps reduce disputes or returns due to method differences.
For factories, the revision means higher testing costs but also an opportunity to eliminate outdated capacity. Crude practices of 'adding antibacterial agent and claiming efficacy' will become unsustainable, while companies with stable processes and testing capabilities will gain stronger bargaining power in the new round of standard upgrades.
